小剂量聚乙二醇干扰素α-2a联合利巴韦林抗病毒治疗失代偿期丙型肝炎肝硬化的临床分析

摘要

Objective:To approach clinical result of curing decompensated C hepatitis cirrhosis by small dose pegylated interferonα -2a and ribavirin. Method:To analyze clinical data of decompensated C hepatitis cirrhosis patients in our hospital,which was to be divided into,control group(ordinary treatment group)30 cases and detection group(small dose of pegylated interferonα-2a in combination with ribavirin antiviral therapy group)30 cases. Result:ALT,AST,ALB,TBIL,child pugh score,HA,PCⅢ,LN of detection group were better than control group,P<0.05,results the difference was statistically significant. Conclusion:The curing decompensated C hepatitis cirrhosis by small dose pegylated interferonα-2a and ribavirin were obviously,anti fibrosis effect is good.%　　目的：探讨小剂量聚乙二醇干扰素α-2a联合利巴韦林抗病毒治疗失代偿期丙型肝炎肝硬化的临床效果。方法：分析我院收治的失代偿丙型肝炎肝硬化患者临床资料,依据治疗方式不同进行分组,对照组(普通治疗组)30例和观察组(小剂量聚乙二醇干扰素α-2a联合利巴韦林抗病毒治疗组)30例。结果：观察组失代偿丙型肝炎肝硬化患者ALT、AST、ALB、TBIL、child pugh评分、HA、PCⅢ、LN均优于对照组,P<0.05,研究结果差异有统计学意义。结论：小剂量聚乙二醇干扰素α-2a联合利巴韦林抗病毒治疗失代偿丙型肝炎肝硬化临床症状改善明显,抗纤维化效果较好。